News
CLLS
1.413
-6.44%
-0.097
Cellectis Is Maintained at Overweight by Barclays
Dow Jones · 10h ago
Cellectis Price Target Cut to $4.00/Share From $5.00 by Barclays
Dow Jones · 10h ago
Barclays Maintains Overweight on Cellectis, Lowers Price Target to $4
Benzinga · 10h ago
Cellectis price target lowered to $4 from $5 at Barclays
TipRanks · 16h ago
Barclays Sticks to Their Buy Rating for Cellectis SA (CLLS)
TipRanks · 16h ago
Cellectis Reports Q1 2025 Financial Results and Strategic Progress
TipRanks · 20h ago
Cellectis Reports Q1 2025 Financial Results and Strategic Developments
TipRanks · 1d ago
Cellectis S.A. Releases Q1 2025 Financial Results
TipRanks · 1d ago
CELLECTIS Q1 REVENUE USD 113.304 MILLION
Reuters · 1d ago
Here are the major earnings after the close today
Seeking Alpha · 1d ago
Weekly Report: what happened at CLLS last week (0505-0509)?
Weekly Report · 1d ago
Earnings Scheduled For May 12, 2025
Benzinga · 1d ago
Cellectis Q1 2025 Earnings Preview
Seeking Alpha · 4d ago
Monthly information on share capital and company voting rights
Barchart · 6d ago
Cellectis to Announce Q1 2025 Financial Results on May 12
TipRanks · 05/06 21:32
Weekly Report: what happened at CLLS last week (0428-0502)?
Weekly Report · 05/05 09:38
Cellectis Unveils Gene Editing Innovations at ASGCT Meeting
TipRanks · 04/28 20:57
Cellectis Presents Research Data On TALEN And TALEB Technologies For Gene And Cellular Therapies At ASGCT Annual Meeting
Benzinga · 04/28 20:33
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
Barchart · 04/28 15:30
Weekly Report: what happened at CLLS last week (0421-0425)?
Weekly Report · 04/28 09:41
More
Webull provides a variety of real-time CLLS stock news. You can receive the latest news about Cellectis through multiple platforms. This information may help you make smarter investment decisions.
About CLLS
More
Cellectis SA is a France-based company active in the field of genome engineering and genomic surgery. The Company specializes in the research, development, and commercialization of rational genome engineering technologies. The Company develops immunotherapies that aim to force the immune system to target and eradicate cancer cells. It has developed an expertise in combining meganucleases with engineered targeting Deoxyribonucleic Acid (DNA) matrices into Meganuclease Recombination Systems (MRS), used for gene excision, correction or replacement. Cellectis SA markets its technologies mainly for use in the research field, in pharmaceutical drug discovery programs, in the agronomics, bioproduction, and biotherapeutics fields. Cellectis SA operates several subsidiaries. The Company operates in France and the United States, among others.